Partner Monica Chmielewski was quoted in an article for Wolters Kluwer Health, “Strategic Perspectives: Compliance with Common Rule burden-reduction provisions might be disruptive,” about the implications of recent updates to the Common Rule and their effects on clinical research.
Chmielewski pointed out that the implementation of a policy requiring the use of single Institutional Review Boards (sIRBs) for clinical research involving multiple study sites requires IRBs to determine which one will serve as the reviewing organization. She also noted that IRBs are working together to participate in collaborations in order to agree which will serve as the sIRB and which will cede review. The IRB chosen to serve as the sIRB often requires an agreement with an indemnification commitment and will try to disclaim liability and damages, she said.
(Subscription required.)
Chmielewski pointed out that the implementation of a policy requiring the use of single Institutional Review Boards (sIRBs) for clinical research involving multiple study sites requires IRBs to determine which one will serve as the reviewing organization. She also noted that IRBs are working together to participate in collaborations in order to agree which will serve as the sIRB and which will cede review. The IRB chosen to serve as the sIRB often requires an agreement with an indemnification commitment and will try to disclaim liability and damages, she said.
(Subscription required.)
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."